Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.39 |
| ▸ | NOS2 | P35228 | 5/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747795 | 0.80 | SMN1; SMN2 (0.46) | NOS3NOS2IKBKBNPC1RAB9A | |
| SCHEMBL21747948 | 0.79 | TLR8 (0.40) | NOS3NOS2CDK5CDK5R1CCNT1 | |
| SCHEMBL2954177 | 0.78 | NOS3 (0.52) | NOS3NOS2NOS1DYRK1AIKBKB | |
| SCHEMBL29745025 | 0.78 | NOS3 (0.52) | NOS3NOS2NOS1DYRK1AIKBKB | |
| SCHEMBL24344928 | 0.77 | MAOA (0.40) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL17254611 | 0.77 | NOS2 (0.56) | NOS3NOS2NOS1DYRK1AIKBKB | |
| SCHEMBL22235384 | 0.77 | NOS3 (0.41) | NOS3NOS2NOS1DYRK1AIKBKB | |
| SCHEMBL5942340 | 0.77 | ALDH1A1 (0.39) | IKBKBNPC1RAB9AALDH1A1 | |
| SCHEMBL22207151 | 0.75 | DYRK1A (0.45) | NOS3NOS2NOS1DYRK1AIKBKB | |
| SCHEMBL22497887 | 0.75 | NOS3 (0.39) | NOS3NOS2NOS1DYRK1AIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| CN-111467346-B | Pyridone derivatives with tetrahydropyranylmethyl groups | 第一三共株式会社 | 2023-05-16 | — | — | CN | disclosed |
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| US-11279713-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-22 | — | — | US | disclosed |
| US-20220002277-A1 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-06 | — | — | US | disclosed |
| US-20220002277-A1 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-06 | — | — | US | disclosed |
| US-11208403-B2 | Pyridone derivatives having tetrahydropyranylmethyl groups | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-12-28 | — | — | US | disclosed |
| US-11208403-B2 | Pyridone derivatives having tetrahydropyranylmethyl groups | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-12-28 | — | — | US | disclosed |
| CN-109890823-B | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2012020848-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | WO | disclosed |
| EP-2411389-A2 | 9H-PYRROLO[2,3-B: 5,4-C']DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2303882-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002277-A1 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | AXL, TYRO3, LCK | NOS3 1606/4885NOS2 1717/4885NOS1 1438/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | NOS3 641/4885NOS2 575/4885NOS1 418/4885 |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | NOS3 773/4885NOS2 2633/4885NOS1 3094/4885 |
| US-11279713-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | NOS3 641/4885NOS2 575/4885NOS1 418/4885 |
| US-11208403-B2 | Pyridone derivatives having tetrahydropyranylmethyl groups | AXL, TYRO3, PDXK | NOS3 1565/4885NOS2 1817/4885NOS1 1703/4885 |
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | ERBB2, ERBB4, ERBB3 | NOS3 2963/4885NOS2 3306/4885NOS1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.